Changes in plasma haptoglobin and alpha‐2‐macroglobulin in hemophiliacs receiving factor replacement therapy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Plasma proteins were studied in 84 patients with hemophilia A, who were receiving factor replacement therapy. Compared with age‐matched controls, 63 patients (75%) had subnormal haptoglobin and 58 (69%) had elevated alpha‐2‐macroglobulin. Causes for depressed haptoglobin were sought by correlating ABO blood types, liver function tests, factor VIII procoagulant levels, and intensity of yearly exposure to clotting factor products. Subnormal haptoglobin levels in chronically transfused patients may relate in part to hemolysis from AB incompatability. However, depressed haptoglobin levels were also found in group O hemophiliacs without other evidence of hemolysis. Most patients lacked evidence of active liver disease, making synthetic deficiency unlikely. There was close correlation between depressed haptoglobin and severity of clotting factor deficiency. The degree of alpha‐2‐macroglobulin elevation correlated with severity of procoagulant deficiency but not with intensity of clotting factor replacement therapy. Since alpha‐2‐macroglobulin plays a major role in the catabolism of fibrinogen, elevated levels may represent a compensatory increase in response to exogenous fibrinogen contained in the clotting factor concentrates. Alternatively, since alpha‐2‐macroglobulin has potent immunosuppressive properties, the elevation may represent a response to transfused alloantigens. Whatever the underlying cause, it is likely the elevations are due to endogenous production rather than to transfusions since clotting factor concentrates contain minimal amounts of alpha‐2‐macroglobulin.

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalAmerican Journal of Hematology
Volume18
Issue number3
DOIs
StatePublished - Jan 1 1985

Fingerprint

Haptoglobins
Blood Coagulation Factors
Hemolysis
Fibrinogen
Therapeutics
Isoantigens
Liver Function Tests
Factor VIII
Hemophilia A
Immunosuppressive Agents
Liver Diseases
Blood Proteins

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{9b06f8008b424b4ebf629f9a1d4b2bf3,
title = "Changes in plasma haptoglobin and alpha‐2‐macroglobulin in hemophiliacs receiving factor replacement therapy",
abstract = "Plasma proteins were studied in 84 patients with hemophilia A, who were receiving factor replacement therapy. Compared with age‐matched controls, 63 patients (75{\%}) had subnormal haptoglobin and 58 (69{\%}) had elevated alpha‐2‐macroglobulin. Causes for depressed haptoglobin were sought by correlating ABO blood types, liver function tests, factor VIII procoagulant levels, and intensity of yearly exposure to clotting factor products. Subnormal haptoglobin levels in chronically transfused patients may relate in part to hemolysis from AB incompatability. However, depressed haptoglobin levels were also found in group O hemophiliacs without other evidence of hemolysis. Most patients lacked evidence of active liver disease, making synthetic deficiency unlikely. There was close correlation between depressed haptoglobin and severity of clotting factor deficiency. The degree of alpha‐2‐macroglobulin elevation correlated with severity of procoagulant deficiency but not with intensity of clotting factor replacement therapy. Since alpha‐2‐macroglobulin plays a major role in the catabolism of fibrinogen, elevated levels may represent a compensatory increase in response to exogenous fibrinogen contained in the clotting factor concentrates. Alternatively, since alpha‐2‐macroglobulin has potent immunosuppressive properties, the elevation may represent a response to transfused alloantigens. Whatever the underlying cause, it is likely the elevations are due to endogenous production rather than to transfusions since clotting factor concentrates contain minimal amounts of alpha‐2‐macroglobulin.",
author = "Gerald Shulman and James Ballard and Eyster, {M. Elaine}",
year = "1985",
month = "1",
day = "1",
doi = "10.1002/ajh.2830180302",
language = "English (US)",
volume = "18",
pages = "223--233",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Changes in plasma haptoglobin and alpha‐2‐macroglobulin in hemophiliacs receiving factor replacement therapy

AU - Shulman, Gerald

AU - Ballard, James

AU - Eyster, M. Elaine

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Plasma proteins were studied in 84 patients with hemophilia A, who were receiving factor replacement therapy. Compared with age‐matched controls, 63 patients (75%) had subnormal haptoglobin and 58 (69%) had elevated alpha‐2‐macroglobulin. Causes for depressed haptoglobin were sought by correlating ABO blood types, liver function tests, factor VIII procoagulant levels, and intensity of yearly exposure to clotting factor products. Subnormal haptoglobin levels in chronically transfused patients may relate in part to hemolysis from AB incompatability. However, depressed haptoglobin levels were also found in group O hemophiliacs without other evidence of hemolysis. Most patients lacked evidence of active liver disease, making synthetic deficiency unlikely. There was close correlation between depressed haptoglobin and severity of clotting factor deficiency. The degree of alpha‐2‐macroglobulin elevation correlated with severity of procoagulant deficiency but not with intensity of clotting factor replacement therapy. Since alpha‐2‐macroglobulin plays a major role in the catabolism of fibrinogen, elevated levels may represent a compensatory increase in response to exogenous fibrinogen contained in the clotting factor concentrates. Alternatively, since alpha‐2‐macroglobulin has potent immunosuppressive properties, the elevation may represent a response to transfused alloantigens. Whatever the underlying cause, it is likely the elevations are due to endogenous production rather than to transfusions since clotting factor concentrates contain minimal amounts of alpha‐2‐macroglobulin.

AB - Plasma proteins were studied in 84 patients with hemophilia A, who were receiving factor replacement therapy. Compared with age‐matched controls, 63 patients (75%) had subnormal haptoglobin and 58 (69%) had elevated alpha‐2‐macroglobulin. Causes for depressed haptoglobin were sought by correlating ABO blood types, liver function tests, factor VIII procoagulant levels, and intensity of yearly exposure to clotting factor products. Subnormal haptoglobin levels in chronically transfused patients may relate in part to hemolysis from AB incompatability. However, depressed haptoglobin levels were also found in group O hemophiliacs without other evidence of hemolysis. Most patients lacked evidence of active liver disease, making synthetic deficiency unlikely. There was close correlation between depressed haptoglobin and severity of clotting factor deficiency. The degree of alpha‐2‐macroglobulin elevation correlated with severity of procoagulant deficiency but not with intensity of clotting factor replacement therapy. Since alpha‐2‐macroglobulin plays a major role in the catabolism of fibrinogen, elevated levels may represent a compensatory increase in response to exogenous fibrinogen contained in the clotting factor concentrates. Alternatively, since alpha‐2‐macroglobulin has potent immunosuppressive properties, the elevation may represent a response to transfused alloantigens. Whatever the underlying cause, it is likely the elevations are due to endogenous production rather than to transfusions since clotting factor concentrates contain minimal amounts of alpha‐2‐macroglobulin.

UR - http://www.scopus.com/inward/record.url?scp=0021914702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021914702&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830180302

DO - 10.1002/ajh.2830180302

M3 - Article

C2 - 2579546

AN - SCOPUS:0021914702

VL - 18

SP - 223

EP - 233

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -